Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Amanda J Hooper & John R Burnett. (2012)
Dalcetrapib, a cholesteryl ester transfer protein modulator. Expert Opinion on Investigational Drugs 21:9, pages 1427-1432.
Read now
Read now
Olaf Kuhlmann & Katja Heinig. (2011) Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey. Xenobiotica 41:5, pages 430-436.
Read now
Read now
Michael Derks, Markus Abt, Graeme Parr, Georgina Meneses-Lorente, Anne-Marie Young & Mary Phelan. (2010) No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opinion on Investigational Drugs 19:10, pages 1135-1145.
Read now
Read now
Jennifer G Robinson. (2010) Dalcetrapib: a review of Phase II data. Expert Opinion on Investigational Drugs 19:6, pages 795-805.
Read now
Read now
Articles from other publishers (17)
Yanke Yu, Charity Henrich & Diane Wang. (2023)
Assessment of the
drug–drug
interaction potential for therapeutic proteins with pro‐inflammatory activities
. Clinical and Translational Science 16:6, pages 922-936.
Crossref
Crossref
Poonam Giri, Harilal Patel & Nuggehally R. Srinivas. (2019) Use of Cocktail Probe Drugs for Indexing Cytochrome P450 Enzymes in Clinical Pharmacology Studies – Review of Case Studies. Drug Metabolism Letters 13:1, pages 3-18.
Crossref
Crossref
Donald M. Black, Darren Bentley, Sunny Chapel, Jongtae Lee, Emily Briggs & Therese Heinonen. (2018) Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib. Clinical Pharmacokinetics 57:11, pages 1359-1367.
Crossref
Crossref
Niresh Hariparsad, Diane Ramsden, Jairam Palamanda, Joshua G. Dekeyser, Odette A. Fahmi, Jane R. Kenny, Heidi Einolf, Michael Mohutsky, Magalie Pardon, Y. Amy Siu, Liangfu Chen, Michael Sinz, Barry Jones, Robert Walsky, Shannon Dallas, Suresh K. Balani, George Zhang, David Buckley & Donald Tweedie. (2017) Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control. Drug Metabolism and Disposition 45:10, pages 1049-1059.
Crossref
Crossref
Natacha Lenuzza, Xavier Duval, Grégory Nicolas, Etienne Thévenot, Sylvie Job, Orianne Videau, Céline Narjoz, Marie-Anne Loriot, Philippe Beaune, Laurent Becquemont, France Mentré, Christian Funck-Brentano, Loubna Alavoine, Philippe Arnaud, Marcel Delaforge & Henri Bénech. (2014) Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics 41:2, pages 125-138.
Crossref
Crossref
Thu Thuy Nguyen, Henri Bénech, Marcel Delaforge & Natacha Lenuzza. (2016) Design optimisation for pharmacokinetic modeling of a cocktail of phenotyping drugs. Pharmaceutical Statistics 15:2, pages 165-177.
Crossref
Crossref
Janne T. Backman, Anne M. Filppula, Mikko Niemi & Pertti J. Neuvonen. (2015) Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacological Reviews 68:1, pages 168-241.
Crossref
Crossref
David RhaindsBenoit J ArsenaultMathieu R BrodeurJean-Claude Tardif. (2012) An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Future Cardiology 8:4, pages 513-531.
Crossref
Crossref
Tisha R. Joy. (2012) Novel HDL-based therapeutic agents. Pharmacology & Therapeutics 135:1, pages 18-30.
Crossref
Crossref
Michael Derks, Hitoshi Kawamura, Markus Abt, Georgina Meneses-Lorente, Mary Phelan & Tomohiro Ishikawa. (2011) Effects of Food Intake on the Pharmacokinetic Properties of Dalcetrapib: Findings From Three Phase I, Single-Dose Crossover Studies in Healthy Volunteers. Clinical Therapeutics 33:6, pages 754-765.
Crossref
Crossref
Michael Derks, Judith Anzures-Cabrera, Lynn Turnbull & Mary Phelan. (2012) Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects. Clinical Drug Investigation 31:5, pages 325-335.
Crossref
Crossref
Michael Derks, Judith Anzures-Cabrera, Lynn Turnbull & Mary Phelan. (2011) Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects. Clinical Drug Investigation, pages 1.
Crossref
Crossref
Marta A Miyares. (2011) Anacetrapib and Dalcetrapib: Two Novel Cholesteryl Ester Transfer Protein Inhibitors. Annals of Pharmacotherapy 45:1, pages 84-94.
Crossref
Crossref
Michael Derks, Markus Abt & Mary Phelan. (2010) Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe. British Journal of Clinical Pharmacology 70:6, pages 825-833.
Crossref
Crossref
Michael Derks, Markus Abt, Mary Phelan, Lynn Turnbull, Georgina Meneses‐Lorente, Nuria Bech, Anne‐Marie White & Graeme Parr. (2013) Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drug‐Drug Interactions. The Journal of Clinical Pharmacology 50:10, pages 1188-1201.
Crossref
Crossref
J B Dumond, M Vourvahis, N L Rezk, K B Patterson, H-C Tien, N White, S H Jennings, S O Choi, J Li, M J Wagner, N M La-Beck, M Drulak, J P Sabo, M A Castles, T R MacGregor & A D M Kashuba. (2010) A Phenotype–Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir. Clinical Pharmacology & Therapeutics 87:6, pages 735-742.
Crossref
Crossref
Michael H. Davidson & Robert S. Rosenson. (2009) Novel Targets that Affect High-Density Lipoprotein Metabolism: The Next Frontier. The American Journal of Cardiology 104:10, pages 52E-57E.
Crossref
Crossref